PL4301748T3 - Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu - Google Patents
Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozyduInfo
- Publication number
- PL4301748T3 PL4301748T3 PL22708569.3T PL22708569T PL4301748T3 PL 4301748 T3 PL4301748 T3 PL 4301748T3 PL 22708569 T PL22708569 T PL 22708569T PL 4301748 T3 PL4301748 T3 PL 4301748T3
- Authority
- PL
- Poland
- Prior art keywords
- triazolyl
- methyl substituted
- substituted alpha
- galactopyranoside
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021055348 | 2021-03-03 | ||
| PCT/EP2022/055224 WO2022184755A1 (en) | 2021-03-03 | 2022-03-02 | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4301748T3 true PL4301748T3 (pl) | 2025-09-08 |
Family
ID=80682779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22708569.3T PL4301748T3 (pl) | 2021-03-03 | 2022-03-02 | Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20240109930A1 (pl) |
| EP (1) | EP4301748B1 (pl) |
| JP (1) | JP7771205B2 (pl) |
| KR (1) | KR20230154221A (pl) |
| CN (1) | CN116888113A (pl) |
| AU (1) | AU2022228660A1 (pl) |
| BR (1) | BR112023017624A2 (pl) |
| CA (1) | CA3209917A1 (pl) |
| CL (1) | CL2023002578A1 (pl) |
| ES (1) | ES3033422T3 (pl) |
| HR (1) | HRP20250833T1 (pl) |
| HU (1) | HUE072194T2 (pl) |
| IL (1) | IL305581A (pl) |
| MA (1) | MA63589B1 (pl) |
| MX (1) | MX2023010241A (pl) |
| PL (1) | PL4301748T3 (pl) |
| RS (1) | RS67032B1 (pl) |
| TW (1) | TWI905393B (pl) |
| UA (1) | UA130562C2 (pl) |
| WO (1) | WO2022184755A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| WO2022073969A1 (en) | 2020-10-06 | 2022-04-14 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| US12291520B2 (en) | 2020-11-02 | 2025-05-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives |
| JP7844491B2 (ja) | 2021-02-09 | 2026-04-13 | イドルシア・ファーマシューティカルズ・リミテッド | ヒドロキシヘテロシクロアルカン－カルバモイル誘導体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| KR102231732B1 (ko) | 2012-10-10 | 2021-03-23 | 갈렉틴 테라퓨틱스, 인크. | 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물 |
| IN2015DN02573A (pl) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| EP2919802A4 (en) | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| CA2970062C (en) | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| ES2734713T3 (es) | 2015-07-06 | 2019-12-11 | Gilead Sciences Inc | Moduladores Cot y métodos de utilización de los mismos |
| CA3062649A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| KR102626669B1 (ko) | 2017-05-12 | 2024-01-17 | 갈랙틴 사이언시즈, 엘엘씨 | 질환의 예방 및 치료를 위한 화합물 및 이의 용도 |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| WO2019075045A1 (en) | 2017-10-11 | 2019-04-18 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| JP2021501180A (ja) | 2017-10-31 | 2021-01-14 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用 |
| US11447517B2 (en) | 2018-11-21 | 2022-09-20 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| US12269819B2 (en) | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| JP7674276B2 (ja) | 2019-07-03 | 2025-05-09 | ガレクト バイオテック エービー | ガレクチンの新規なガラクトシド阻害剤 |
| CA3143078A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| KR102863667B1 (ko) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
-
2022
- 2022-03-02 WO PCT/EP2022/055224 patent/WO2022184755A1/en not_active Ceased
- 2022-03-02 KR KR1020237033375A patent/KR20230154221A/ko active Pending
- 2022-03-02 HR HRP20250833TT patent/HRP20250833T1/hr unknown
- 2022-03-02 MX MX2023010241A patent/MX2023010241A/es unknown
- 2022-03-02 CA CA3209917A patent/CA3209917A1/en active Pending
- 2022-03-02 UA UAA202304634A patent/UA130562C2/uk unknown
- 2022-03-02 IL IL305581A patent/IL305581A/en unknown
- 2022-03-02 EP EP22708569.3A patent/EP4301748B1/en active Active
- 2022-03-02 CN CN202280017484.3A patent/CN116888113A/zh active Pending
- 2022-03-02 JP JP2023552539A patent/JP7771205B2/ja active Active
- 2022-03-02 PL PL22708569.3T patent/PL4301748T3/pl unknown
- 2022-03-02 BR BR112023017624A patent/BR112023017624A2/pt unknown
- 2022-03-02 TW TW111107565A patent/TWI905393B/zh active
- 2022-03-02 AU AU2022228660A patent/AU2022228660A1/en active Pending
- 2022-03-02 US US18/548,833 patent/US20240109930A1/en active Pending
- 2022-03-02 ES ES22708569T patent/ES3033422T3/es active Active
- 2022-03-02 MA MA63589A patent/MA63589B1/fr unknown
- 2022-03-02 RS RS20250732A patent/RS67032B1/sr unknown
- 2022-03-02 HU HUE22708569A patent/HUE072194T2/hu unknown
-
2023
- 2023-08-31 CL CL2023002578A patent/CL2023002578A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023017624A2 (pt) | 2023-10-10 |
| CL2023002578A1 (es) | 2024-03-22 |
| RS67032B1 (sr) | 2025-08-29 |
| HUE072194T2 (hu) | 2025-10-28 |
| US20240109930A1 (en) | 2024-04-04 |
| JP7771205B2 (ja) | 2025-11-17 |
| MX2023010241A (es) | 2023-09-12 |
| TWI905393B (zh) | 2025-11-21 |
| UA130562C2 (uk) | 2026-03-18 |
| IL305581A (en) | 2023-10-01 |
| AU2022228660A1 (en) | 2023-10-19 |
| EP4301748C0 (en) | 2025-05-07 |
| JP2024509421A (ja) | 2024-03-01 |
| WO2022184755A1 (en) | 2022-09-09 |
| EP4301748A1 (en) | 2024-01-10 |
| HRP20250833T1 (hr) | 2025-09-12 |
| CA3209917A1 (en) | 2022-09-09 |
| EP4301748B1 (en) | 2025-05-07 |
| CN116888113A (zh) | 2023-10-13 |
| MA63589B1 (fr) | 2025-07-31 |
| TW202300146A (zh) | 2023-01-01 |
| KR20230154221A (ko) | 2023-11-07 |
| ES3033422T3 (en) | 2025-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4199925B1 (en) | ORETIN RECEPTOR AGONISTS CYCLOPENTAPYRROLE | |
| PT3958977T (pt) | Derivados de camptotecina | |
| IL292161A (en) | New methylquinazolinone derivatives | |
| EP4253377A4 (en) | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | |
| EP4744661A2 (en) | NEW PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | |
| EP4013751C0 (en) | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | |
| DK3768674T3 (da) | Aminopyrimidinderivater som ctps1-hæmmere | |
| HUE072194T2 (hu) | Triazolil-metil-szubsztituált alfa-D-galaktopiranozid származékok | |
| EP4272364A4 (en) | TA NTN REPORT | |
| EP4077334C0 (en) | FUROINDAZOLE DERIVATIVES | |
| EP4021904C0 (en) | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | |
| IL304774A (en) | Enhanced sophorolipid derivatives | |
| DK3823970T3 (da) | Yderligere substituerede triazoloquinoxalinderivater | |
| DK4396183T3 (da) | Substituerede s-alaninatderivater | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| EP4416054A4 (en) | MULTICOPTER | |
| EP4308572C0 (en) | NEW THIENOPYRIMIDINONE DERIVATIVES | |
| EP4507692A4 (en) | TRYPTAMINE DERIVATIVES | |
| EP4308576C0 (en) | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | |
| DK3894410T3 (da) | Substituerede xanthinderivater | |
| EP4373959A4 (en) | NICK-LIGAT STLFR | |
| EP4166541A4 (en) | Dimethylsulfoximine derivative | |
| EP4320989A4 (en) | MR-DC IMPROVEMENTS | |
| EP4457227A4 (en) | QUINOLEIN DERIVATIVE SUBSTITUTE | |
| EP4361159A4 (en) | Borono-phenylalanine derivative |